Drug Profile

ORKA 002

Alternative Names: ORKA 021; ORKA-002; PR-029

Latest Information Update: 18 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Paragon Therapeutics
Developer Oruka Therapeutics; Paragon Therapeutics
Class Antibodies; Antipsoriatics; Antirheumatics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Interleukin 17 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Hidradenitis suppurativa; Plaque psoriasis
Phase I Psoriatic arthritis

Most Recent Events

10 Aug 2026 Phase-II clinical trials in Hidradenitis suppurativa in USA, Canada (SC)
10 Aug 2026 Oruka plans to initiate phase II trials (Combination therapy) in 2027 (SC)
19 Mar 2026 Phase-II clinical trials in Plaque psoriasis in Canada (SC) (NCT07474792)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com